• U.S. FDA declines to approve Spectrum Pharmaceuticals' lung cancer drug By Reuters

    4 days ago - By Up Worthy

    Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration declined to approve its experimental lung cancer drug, citing the need for an additional study. The company now plans to de-prioritize the development of the drug, called poziotinib, and said it was... spectrumpharmaceuticals additionalstudy experimentallung lungcancer cancerdrug fda drug pharmaceuticals spectrum saudiarabia
    Read more ...